Printed from Voxsanity (voxsanity.com.au) — NCT06024746 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Heart Disease
Phase 3 Heart Disease Trial, Recruiting
NCT06024746
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to give consent (either personally or through an authorised representative, as allowed by local rules)
- People aged 18 or older (or the legal age of adulthood in their country)
- People who are currently in hospital, or who have recently been discharged, with a primary diagnosis of heart failure
- People who had signs and symptoms of heart failure at the time they were admitted to hospital
- People whose blood test results during this hospital stay (or within 72 hours before admission) showed elevated heart failure markers above specific levels — either NTproBNP or BNP — with different thresholds depending on whether the person has a normal heart rhythm or atrial fibrillation (confirm specific values with trial site)
- People who have met certain medical stability requirements defined by the trial, if they are still in hospital at the time of enrolment (confirm with trial site)
- People who received at least one intravenous dose of a water-removing medication called a loop diuretic (such as furosemide) during this hospital stay
- Female participants who have a negative pregnancy test and agree to use adequate contraception during the trial
Who may not be able to join:
- People with a diagnosis of type 1 diabetes, or who have previously had a condition called diabetic ketoacidosis
- People with a documented history of severely high potassium levels while taking a type of heart medication called a mineralocorticoid receptor antagonist (MRA)
- People currently being treated with a non-steroidal MRA or a medication from the SGLT2 inhibitor class
- People whose kidney function is below a certain level, or whose blood potassium level is above 5.0 mmol/L (confirm with trial site)
- People who had a heart attack, a procedure to open blocked heart arteries, a heart valve repair or replacement, or a specific type of heart device implanted within the past 30 days
- People who have previously had a heart transplant, or for whom a heart transplant is planned
- People whose heart failure is primarily caused by a significant, uncorrected problem with one or more heart valves
- People whose heart muscle disease is caused by certain specific conditions, including acute heart inflammation, storage or infiltrative diseases, muscular dystrophies, reversible causes, a condition called hypertrophic obstructive cardiomyopathy, complex heart defects present from birth, or constriction around the heart
- People whose heart failure symptoms are likely caused by something other than heart failure itself
- People taking certain other medications that interact with the way the trial drug is processed by the body (confirm specific medications with trial site)
- People with a known allergic reaction to the trial medication or any of its ingredients
- People with any other medical condition or treatment that the trial team determines would make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: (303) 860-9900
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Colorado Prevention Center
Registry
ClinicalTrials.gov
Start date
9 July 2024
Est. completion
1 July 2026
Where this trial is recruiting
🇧🇷 Brazil
🇨🇦 Canada
🇺🇸 United States
Primary endpoints
Clinical benefit; Number of serious adverse events (AEs).; Number of adverse events leading to discontinuation of study drug.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.